Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LATITUDE-PsA-3001: Zasocitinib vs Placebo and Apremilast in Biologic-Naïve Psoriatic Arthritis
2024-513111-27-00Phase 3Authorised
- Sponsor
- Takeda
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial of zasocitinib in psoriatic arthritis (PsA) (4 arms), sponsored by Takeda. Primary endpoint: ACR20 response at Week 16. Planned start Jun 2025; status: authorised.
02
Drugs
zasocitinib
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2024-513111-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513111-27-00.